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Severe X-Linked Mitochondrial Encephalomyopathy
Associated with a Mutation in Apoptosis-Inducing Factor
Daniele Ghezzi,1 Irina Sevrioukova,2 Federica Invernizzi,1 Costanza Lamperti,1 Marina Mora,3
Pio D’Adamo,4 Francesca Novara,5 Orsetta Zuffardi,5 Graziella Uziel,6 and Massimo Zeviani1,*
We investigated two male infant patients who were given a diagnosis of progressive mitochondrial encephalomyopathy on the basis of
clinical, biochemical, and morphological features. These patients were born from monozygotic twin sisters and unrelated fathers, sug-
gesting an X-linked trait. Fibroblasts from both showed reduction of respiratory chain (RC) cIII and cIV, but not of cI activities. We found
a disease-segregating mutation in the X-linked AIFM1 gene, encoding the Apoptosis-Inducing Factor (AIF) mitochondrion-associated 1
precursor that deletes arginine 201 (R201 del). Under normal conditions, mature AIF is a FAD-dependent NADH oxidase of unknown
function and is targeted to the mitochondrial intermembrane space (this form is called AIFmit). Upon apoptogenic stimuli, a soluble
form (AIFsol) is released by proteolytic cleavage and migrates to the nucleus, where it induces ‘‘parthanatos,’’ i.e., caspase-independent
fragmentation of chromosomal DNA. In vitro, the AIFR201 del mutation decreases stability of both AIFmit and AIFsol and increases the
AIFsol DNA binding afﬁnity, a prerequisite for nuclear apoptosis. In AIF
R201 del ﬁbroblasts, staurosporine-induced parthanatos was mark-
edly increased, whereas re-expression of AIFwt induced recovery of RC activities. Numerous TUNEL-positive, caspase 3-negative nuclei
were visualized in patient #1’s muscle, again indicating markedly increased parthanatos in the AIFR201 del critical tissues. We conclude
that AIFR201 del is an unstable mutant variant associated with increased parthanatos-linked cell death. Our data suggest a role for AIF in
RC integrity andmtDNAmaintenance, at least in some tissues. Interestingly, riboﬂavin supplementation was associated with prolonged
improvement of patient #1’s neurological conditions, as well as correction of RC defects in mutant ﬁbroblasts, suggesting that stabili-
zation of the FAD binding in AIFmit is beneﬁcial.A peculiar feature of mitochondrial disorders is that only
a minority are caused by mutations directly affecting the
structural components of the respiratory chain (RC)
complexes.1 In fact, the vast majority of mitochondrial-
disease gene products are involved in ancillary roles con-
cerning RC formation, activity, and turnover.1 Far from
being diminutive, this characteristic has allowed scientists
to exploit human mitochondrial disorders to dissect and
characterize in detail the mitochondrial machinery at
the molecular level. A further consideration is that mito-
chondrial RC not only catalyzes oxidative phosphoryla-
tion (OXPHOS) and thus provides most ATP, the universal
energy currency of cells, but is also at the cross-point of
a number of other crucial functions, including heat
production, ion trafﬁcking, nucleotide synthesis, genera-
tion of reactive oxygen species (ROS), and apoptosis.1,2
In addition, several RC-associated proteins play multiple
roles and may be located in different cell compartments,
besides mitochondria.3 Consequently, OXPHOS impair-
ment determines not only various degrees of energy
failure but also multiple additional effects that account,
at least in part, for the intricacy and complexity of mito-
chondrial disorders.2,4 Primary mutations in the mtDNA
or of nuclear genes encoding proteins directly involved
in RC functioning can cause homeostatic alterations and
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The Amto the pathological mechanism.2 Is this a two-way
correlation? In other terms, could defective RC and faulty
OXPHOS be caused by primary abnormalities of such
pathways and eventually lead to a mitochondrial disease?
In support to this idea, we report here the results of genetic
and molecular investigation on two male infant patients
affected by severe encephalomyopathy and OXPHOS
failure associated with a deleterious mutation in AIF,
a master gene product of mitochondrial programmed cell
death.5,6
Patient #1 was born at term after an uneventful preg-
nancy; an elder brother was healthy. Birth weight was
3000 g, and the Apgar score was 9-9. He was breastfed
and had frequent regurgitations, but his growth remained
normal until 1 year of age. However, from the ﬁrst months
he showed reduced spontaneous motility of the right leg
and continuous involuntary movements of small ampli-
tude in the hands and feet. At 5 months a ﬁrst brain
MRI was normal, but at 1 year the MRI showed bilateral
abnormal signal in the neostriatum (Figures 1A and 1B).
By that time, a moderate psychomotor development delay
in head control had become evident: he achieved head
control at as late as 5 months of age and reached the sitting
position at 10 months. When he was admitted to our
hospital, at 15 months of age, he could not reach and
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Figure 1. Brain Imaging and Skeletal Muscle Morphological
and Histochemical Analysis
(A and B) Magnetic resonance imaging (MRI) T2-weighted (A) and
T1-weighted (B) sequences on a transverse section of supratento-
rial brain of patient #1.
(C)MRI T2-weighted sequence on a transverse section of supraten-
torial brain of patient #2 at 11 months of age.
(D) MRI T1-weighted sequence on a coronal section of supratento-
rial brain of patient #2 at 11 months of age.
(E–H) Patient #2 muscle biopsy showing an increase of connective
tissue, severe variability in ﬁber size, and necrotic and regenerating
ﬁbers at Hematoxylin and Eosin (H&E) (E), numerous ragged-red
ﬁbers under themodiﬁedGomori trichrome staining (F), increased
SDH (succinate dehydrogenase) histochemical staining (G), and
diffuse reduction of COX histochemical reaction (H).examination revealed continuous fasciculations of the
tongue, hypotonia, and areﬂexia. Verbal communication
was limited to modulated babble, but no deﬁned words,
and the general quotient on the Grifﬁth scale was 50.640 The American Journal of Human Genetics 86, 639–649, April 9, 2Lactate and pyruvate were moderately increased in plasma
and cerebro-spinal ﬂuid (CSF). Electromyography and
nerve conduction velocities demonstrated axonal sensory
and motor peripheral neuropathy. Because a CT scan of
quadriceps muscles had shown an unexpectedly severe
grade of muscular atrophy, an openmuscle biopsy was per-
formed so that the possibility of a mitochondrial disorder
could be evaluated. RC activities could not be measured
because the muscle tissue was largely substituted by fat,
but in cultured ﬁbroblasts complex III and IV were partially
reduced (Table 1). Although mtDNA sequence analysis
failed to reveal mutations, its copy number, measured
by quantitative real-time PCR, was reduced to 20% of the
control values in a few muscle ﬁbers dissected out of the
surrounding fat. However, mtDNA amount was normal
in cultured ﬁbroblasts. The patient was discharged from
the hospital, but after a few days he developed seizures
and severe respiratory distress needing assistance from
the intensive care unit. The neurological conditions
steadily worsened thereafter, and there was severe psycho-
motor regression: sitting and head control were lost, and
environment contact became poor and then lost. Interest-
ingly, riboﬂavin supplementation (30 mg/day) led to
improvement of his clinical conditions for the following
7 months: he recovered the ability to sit unaided, grasp
objects, and communicate with his parents in spite of
generalized severe weakness. At two years, he suddenly
developed generalized seizures, partially controlled by
phenobarbital, and severe respiratory insufﬁciency with
bronchopneumonia, which required mechanical ventila-
tion and tracheotomy. He is now 5 years old and still alert,
but he is virtually unable to communicate, is tetraplegic
and wheelchair bound, and is under permanent artiﬁcial
ventilation.
Patient #2 was the only child of nonconsanguineous
parents. His mother was a monozygotic twin sister of the
mother of patient #1. He was born by caesarean section
because of fetal cardiac rhythm deceleration, but no
problems were reported during the perinatal period. His
psychomotor development was reported as normal until
the age of 11 months, when a reduction of active move-
ments and subsequent psychomotor regression were
noticed. A brain MRI showed abnormal bilateral signal
intensities in the neostriatum (Figures 1C and 1D). At
1 year of age, he presented with marked irritability, severe
hypotonia, hypo-areﬂexia, muscle wasting, and weakness.
He could sit unaided for just a few seconds andhadnoactive
movement of the lower limbs; his generalized quotient
on the Grifﬁth scale was 34. Plasma lactate was increased
up to 3150 mM (normal < 2000 mM). H & E staining
of a muscle biopsy showed dystrophic alterations with
areas of small, regenerating ﬁbers, next to areas with
degenerating ﬁbers (Figure 1E) but no type grouping (not
shown); Gomori trichrome staining showed several
ragged-red ﬁbers (Figure 1F), which corresponded to SDH-
hyperintense ﬁbers (Figure 1G); the ﬁbers were diffusely
pale or unreactive to cytochrome-c-oxidase (COX)-speciﬁc010
Table 1. Biochemical Analysis of OXPHOS Activities
CSa cI cII SDH cIII cIV cV Treatment
Muscle
Ct values 80–210 13–24 15–28 10.7–17.4 88–167 120–220 130–280
Pt#2 ms 153 7.9 (43) 13.6 (63) 8.9 (63) 56 (43) 19 (11) 71 (35)
Fibroblasts
Ct values 100–200 10.7–26 8.6–18.4 6.5–14.3 70–120 95–150 65–113
Primary Fibroblasts
Pt#1 fbs 144 13.5 (73) 9.4 (70) 9.3 (89) 63 (66) 66 (54) 100 (112) no
Pt#2 fbs 187 15.2 (82) 15.6 (116) 10 (96) 66 (69) 87,5 (71) 205 (230) no
Pt#1 fbs 91 9.4 (51) 14 (104) 10.5 (101) 50.4 (53) 67.4 (55) 88.1 (99) 48 hr galactose
Pt#2 fbs 111 5.9 (32) 17 (126) 10.7 (103) 40.9 (43) 66.2 (54) 97 (109) 48 hr galactose
SV40-Immortalized Fibroblasts Treated with Riboflavin
Pt#2 SV40 fbs 128 11,4 (62) 11,1 (82) 7,1 (68) 41,8 (44) 84,5 (69) 107,7 (121)
Fbs immortalized with
pBabe-puro SV40Pt#1 SV40 fbs 154 11,6 (63) 18,1 (134) 8,5 (82) 33,9 (36) 73 (60) 97 (109)
Pt#1 SV40 fbs 174 n.d n.d n.d 58,9 (62) 88,2 (72) n.d. 1 week riboﬂavin
Immortalized Fibroblasts Transfected with an AIF-Expressing Eukaryotic Vector
Pt#1 SV40 fbs mock 147 11,8 (63) 20,6 (152) 12 (115) 29,5 (31) 69,9 (57) 67,7 (76) SV40-fbs transfected with
empty pcDNA3.1
Pt#1 SV40 fbsþAIF 123 11,9 (65) 16,3 (121) 12,2 (117) 45,2 (48) 93,6 (77) 68,5 (77) SV40-fbs transfected with
pcDNA3.1 þ AIF
All enzymatic activities are normalized for citrate synthase (CS) activity. The percentages of the mean control value are shown in parentheses. Values less than
control values are shown in italics. Abbreviations are as follows: n.d., not determined; Ms, skeletal muscle biopsy; fbs, fibroblasts.
a nmol/min mg.histochemistry (Figure 1H). The activity of respiratory-
chain complexes in muscle was reduced, especially that of
COX (complex IV, cIV), which was as low as 11% of the
normalmean. Similar tohis cousin, patient #2had complex
III and IV activities that were below the normal range in
ﬁbroblasts (Table 1). Mitochondrial DNA depletion (about
35% of control value) was again present in muscle but not
in ﬁbroblasts. The patient suddenly died at 16 months of
age during sleep. No autopsy was performed. The parents
gave informed consent to a genetic screening according to
the Ethical Committee of the Neurological Institute ‘‘Carlo
Besta,’’ Milan, Italy.
Because our two patients were born from genetically
proven (not shown) monozygotic twin sisters and from
unrelated fathers (Figure 2A), we hypothesized either an
mtDNA- or an X-linked trait. The former hypothesis was
ruled out by sequence analysis of a normal haplogroup J1
mtDNA in all of the maternal family members, including
the two propositi. Next, we carried out SNP-based haplotype
analysis of the X chromosome. In the blood DNA extracted
from the two patients, we found a haploidentical region
between markers RS5977571 and RS5904872; this region
contained 211 entries, only 75 of which corresponded to
allegedly expressed protein-encoding genes. The remaining
entries corresponded to pseudo-genes and micro-RNA-
encoding genes. We prioritized the 75 gene sequences onThe Amthe basis of known or putative mitochondrial localization
of the corresponding proteins. Seven genes within the
critical interval encode predicted mitochondrial proteins
on the basis of combined analysis with mitochondrial-
protein prediction software, including Mitprot, Target-P,
Predotar, and Wolf-Psort (Table S1). However, two entries,
LOC100131049 and LOC728470, were discarded because
no expressed sequence tags are present in the NCBI
database, suggesting that neither one corresponds to
an expressed gene. Two additional genes, SLC9A6 (MIM
*300231) and FLJ30058, encode proteins whose function
is known and that are not localized in mitochondria. In
particular, mutations in SLC9A6 are associated with an
Angelman-like syndrome (MIM #300243), and its corre-
sponding protein has been localized to endosomes rather
than to mitochondria.7 FLJ30058 is predicted to encode
a Rho-GAP, a GTPase activator protein, involved in the
regulation of cell cycle and cytoskeleton formation.
Sequence analysis of the exons and exon-intron boundaries
of both BMCP1 (MIM *300242) and FAM127C failed to
show mutations. However, sequence analysis of AIFM1
(Apoptosis-inducing factor mitochondrion-associated 1,
MIM *300169), revealed in both patient #1 (III-2, Figure 2A)
andpatient #2 (III-3, Figure2A) ahomozygous trinucleotide
deletion (c.del601-603) in exon5 (Figure 2B), predicting the
ablation of an arginine (R) residue at position 201 of the AIFerican Journal of Human Genetics 86, 639–649, April 9, 2010 641
Figure 2. Pedigree and AIF Features
(A) Pedigree of the family. Filled symbols indicate affected individuals (patient #1, Pt#1 and patient #2, Pt#2, also indicated by arrows).
WT and DR201 indicate the presence of wild-type AIF sequence and the presence of the R201 deletion, respectively.
(B) Sequence analysis of exon 5 of AIFM1 showing the c.601–603 deletion in patient #1. A control sequence is shown for comparison.
(C) Schematic primary structure of the AIF protein. MTS indicates the mitochondrial targeting sequence; TM indicates a putative trans-
membrane domain. MPP: Mitochondrial Processing Peptidase.
The precursor, mitochondrial (AIFmit), and soluble (AIFsol) forms of the AIF protein are shown starting from the N-terminal aminoacid;
the corresponding molecular weights are also indicated.polypeptide (R201 del). The two twinmothers (II-2 and II-4,
Figure 2A)were both heterozygous for this change, whereas
the mutation was absent in all other family members,
including the maternal grandfather (I-1) and grandmother
(I-2), maternal aunt (II-6), and the fathers (II-1 and II-3) of
the probands, as well as the healthy brother of patient #1
(III-1). It was also absent in 210 alleles from Italian control
samples. Taken together, these results suggest the occur-
rence of a de novo mutational event in the zygote gener-
ating the twin sisters, although germinal mosaicism of the
patients’ grandmother or grandfather cannot be excluded.
To test whether the R201 del mutation is pathogenic and
responsible for the disease phenotype, we ﬁrst investigated
the mutant variant by in silico and in vitro analyses.
The AIF precursor protein is a 67 kDa polypeptide (Fig-
ure 2C) encoded by a gene located on chromosome
Xq25-26. After mitochondrial import and cleavage of a
54-amino-acid-long mitochondrial targeting sequence,
the 62 kDa, mitochondrion-speciﬁc mature AIF protein
(AIFmit, Figure 2C) noncovalently binds FAD and attaches
by an N-terminal trans-membrane domain to the inner
mitochondrial membrane, from where it projects toward
the mitochondrial inter-membrane space.8–10 Minor pools
of the protein have (controversially) been proposed to
occupy the outer mitochondrial membrane11 or be free
in solution within the inter-membrane space. In the latter642 The American Journal of Human Genetics 86, 639–649, April 9, 2compartment, mature AIFmit homodimers function as a
FAD-dependent NADH oxidase, which takes part in an
unknown metabolic pathway, possibly involved in ROS
control or redox sensing. Upon presentation of apopto-
genic stimuli, a soluble form of AIF (AIFsol) is produced
by protease-mediated cleavage of AIFmit at position 102
(Figure 2C); this cleavage is mediated by cathepsin-B, L,
and S12 or calpain.13 AIFsol then translocates from mito-
chondria to the nucleus, where it binds to chromosomal
DNA and induces chromatin condensation and DNA
fragmentation by attracting and activating a set of endo-
nucleases, possibly including endonuclease G,14 another
cell-death executor normally stored in mitochondria.
This caspase- and cytochrome-c-independent, peculiar
form of mitochondrion-driven programmed cell death
has been denominated parthanatos to distinguish it from
caspase-mediated ‘‘conventional’’ apoptosis.15
Mammalian AIFs share>90% amino acid sequence iden-
tity and, as the X-ray structures of human and murine
ﬂavoproteins suggest,16–18 have virtually undistinguish-
able tertiary structures (Figure 3A). Because the crystal
structure of the AIFR201 del variant is yet to be determined,
we have modeled the R201 del mutation in silico. Accord-
ing to the X-ray data, the R201 residue is part of the
AIF-speciﬁc 191–203 b-hairpin, which forms the FAD bind-
ing pouch and confers conformational stability to the010
Figure 3. Structural and In Vitro Analyses of Recombinant AIFwt and AIF201 del
(A) Superimposed X-ray structures of oxidized (NAD-less) human andmurine AIFs (PDB codes: 1M6I and 1DV416,17) show that the R201
(R200 in mouse) assists in the folding of two peptide stretches, near the FAD-binding pocket. The R201 residue, contained in the ﬁrst
stretch (in pink), establishes a link with the second stretch (in brown) by forming a salt bridge with the E531 residue.
(B) In the reduced NAD-bound dimer of murine AIF (PDB code 3GD418), the active form of the ﬂavoprotein, R200 (R201 in humans),
establishes a hydrogen bond with F204, helping the functionally important b-hairpin, including the W195 residue (shown in pink), to
get properly oriented. F204 and W195 correspond to human F205 and W196, respectively.
(C) Computer modeling predicts that deletion of R201 in reduced human AIF can disrupt the H bond with F205 and thus shorten and
distort the 191–203 b-hairpin (rendered in blue for the wild-type and in pink for the mutant).
(D) Anaerobic titration of 15 mMAIFmit
R201 del with NADH (in 50mMphosphate [pH 7.5]). The inset shows that an equimolar amount of
NADH is required to fully reduce FAD.
(E) Oxidation of the NADH-reduced wild-type (wt) and R201 del mutants (mt) of AIFmit and AIFsol. A 15 mM protein solution in 50 mM
phosphate (pH 7.5) was aerobically reduced with a 6-fold excess of NADH, and the FAD oxidation by air oxygenwasmonitored over time
at 452 nm.
(F) Far-UV circular dichroism spectra of 3 mM AIFmit
R201 del were recorded in 10 mM sodium phosphate (pH 7.5) in the absence or pres-
ence of a 20-fold excess of NAD(P)H. The R201 del mutation has no signiﬁcant effect on the redox-dependent changes in the secondary
structure of AIF.
(G) The R201 del mutation promotes the AIFsol-DNA interaction. Equal amounts of wild-type (wt) andmutant (mt) AIFsol were incubated
for 15min with 250 ng of a 100 bp DNA ladder in the absence or presence of a 20-fold excess of NAD(P)H; separation on a 2% agarose gel
and visualization with ethidium bromide followed.
The R201 deletion was introduced into the AIFmit and AIFsol expression plasmids by site-directed mutagenesis with the Stratagene Quik-
Change kit. The mutant proteins were expressed and puriﬁed according to the procedure developed for wild-type AIF.19
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Table 2. Kinetic Properties of AIFWT and AIFR201 del
AIFwt a AIFR201 del
kET
NADH (s1) 0.2 11 5 1
KM
NADH (mM) 0.60 0.35 5 0.03
kET
NADH/KM
NADH 0.3 31 5 2
kET
NADPH (s1) 1.0 3 102 3.35 0.2
KM
NADPH (mM) 3.7 5.05 0.6
kET
NADPH/KM
NADPH 2.7 3 103 0.75 0.1
a Determined previously.19ﬂavoprotein. In oxidized AIF, the R201 residue induces the
folding of the regulatory 510–560 peptide by establishing
a salt bridge with E531 and thus limiting the accessibility
to the FAD-containing active site (Figure 3A). In the
reduced NAD-bound protein, the R201 side chain (R200
in the mouse protein) is expected to be hydrogen-bonded
to the carbonyl oxygen of the neighboring F205 residue
(F204 in the mouse), as observed in murine AIF (Fig-
ure 3B), spatially orienting the solvent-exposed hairpin
and functionally important W196 (murine W195).18
Because R201 deﬁnes the length and positioning of the
hairpin and contributes to the intricate network of polar
and hydrophobic interactions between the 191–203 and
510–539 fragments, its deletion can predictably perturb
the functional properties of both oxidized and reduced
forms of AIF (Figure 3C).
To test these predictions experimentally, we performed
anaerobic titration of recombinant human AIFR201 del
with NADH.19 Once exposed to NADH, the AIFR201 del
variant, similar to wild-type AIF (AIFwt), showed stoichio-
metric reduction of FAD to FADH2 and formation of a
FADH2-NAD charge-transfer complex, characterized by
an absorbance peak in the long-wavelength (z700 nm)
spectral region (Figure 3D). However, the lifetime of the
FADH2-NAD complex formed by mutant AIF
R201 del was
considerably shorter than that observed with AIFwt, but
there was no signiﬁcant difference in t1/2 for the mature
(AIFmit) and apoptogenic forms (AIFsol) (Figure 3E). More-
over, the kinetics of the redox reaction showed that
AIFR201 del accepts the hydrogen atom from NADH or
NADPH at a rate two orders of magnititude faster than
AIFwt, and there is a lower-than-normal preference for
NADH (50-fold versus 100-fold for AIFwt, Table 2). Circular
dichroism spectroscopy data show nearly identical folding
proﬁles for the recombinant mutant versus wild-type AIF
(Figure 3F and Figure 2 in Churbanova et al.19), indicating
that the R201 del mutation mainly affects the functions
but does not drastically alter the structure of the mutant
protein. However, higher sensitivity of AIFR201 del to
trypsin digestion (Figure S1) suggests that subtle conforma-
tional changes caused by the R201 deletion destabilize the
ﬂavoprotein and increase its susceptibility to proteolytic
cleavage. In addition, unlike AIFwt, oxidized AIFR201 del644 The American Journal of Human Genetics 86, 639–649, April 9, 2partially loses FAD during gel ﬁltration (Figure S2), which
can be another indication of structural instability of the
mutant. Taken together, the in vitro results allow us to
propose that AIFR201 del is an unstable variant with altered
redox enzymatic properties.
Next, we tested the DNA binding ability of AIFR201 del,
strictly required for induction of nuclear fragmentation.17
Our DNA retardation assays showed that the R201 deletion
signiﬁcantly increases AIFsol-DNA interaction (Figure 3G).
Whereas AIFwt only moderately affected the electropho-
retic mobility of linearized DNA, the AIFR201 del mutant
protein formed a substantial amount of high-molecular
weight protein-DNA complexes, indicating that AIFR201
del has higher DNA binding afﬁnity and potential propen-
sity to cause DNA damage.
We then investigated the consequences of the AIFR201 del
mutation in cell lines. By immunovisualization on electro-
blotted SDS-PAGE with an anti-AIF speciﬁc antibody,
we ﬁrst ascertained that the amount and processing of
AIFR201 del is similar to those of AIFwt in patient-derived
skin ﬁbroblasts (Figure 4A).
To test whether the AIFR201 del mutant variant is directly
linked to impaired OXPHOS, we analyzed mutant ﬁbro-
blast cell lines grown in a galactose-rich, glucose-free
medium, a condition that forces cells to rely for energy
on mitochondrial respiration rather than glycolysis. After
exposure to galactose (5 mM) for 48 hr, combined deﬁ-
ciency of cI, cIII, and cIV activities was detected in cell
lines derived from both patients (Table 1). Mitotracker-
based visualization of the mitochondrial network showed
marked fragmentation of mitochondria in mutant cells
cultured in galactose, in comparison to the normal ﬁla-
mentous network visualized in glucose-grownmutant cells
and in glucose-grown and the majority of galactose-grown
control cells (Figure 4B). We found that approximately
75% of mutant cells versus 23% control cells showed
mitochondrial fragmentation under galactose treatment
(Figure 4C). Fragmentation of the mitochondrial network
is a well-documented morphological alteration related
to reduced fusion of the mitochondrial membranes and
is typically observed in faulty OXPHOS cells or in pre-
apoptotic conditions.20 Finally, MTT cell viability assay
showed reduced cell growth of mutant ﬁbroblasts in
glucose and showed an even greater reduction of growth
in galactose medium (Figure 4D). Neither in glucose- nor
in galactose-grown cells was reduction of mtDNA ever
found, as opposed to the clear mtDNA depletion detected
in skeletal muscle of both patients. These results indicate
that AIFR201 del is directly involved in RC impairment, inde-
pendently of whether mtDNA is depleted, an effect that
seems to be restricted to, and aggravate the OXPHOS
failure of, speciﬁc tissues, for instance skeletal muscle. To
further test the pathogenic role of AIFR201 del, we expressed
recombinant AIFwt in SV40-immortalized, cIII- and cIV-
defective AIFR201 del mutant ﬁbroblasts by two separate
sets of transfections with a recombinant vector containing
a neomycin-resistant gene as a selectable marker. After010
AIF
SDHA
Actin
Pt#1 Ct
A B DMEM-Glucose
DMEM-Galactose
77
25
23
75
0
20
40
60
80
100
Ct Pt
Normal network Fragmented networkC
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0 1 2 3 4 5 6
Ct glu
Pt#2 glu
Pt#1 glu
Ct gal
Pt#2 gal
Pt#1 gal
D
Days
Ab
s 
(6
50
nm
)
Figure 4. Characterization of Patients’ Fibroblasts before and
after Galactose Treatment
(A) Protein-blot analysis of patient #1(Pt) and control (Ct) skin
cultured ﬁbroblasts, immunodetected with an antibody against
AIF (Chemicon). Antibodies against subunit A of complex II
(SDHA, Invitrogen)andactin (Sigma)wereusedas loadingcontrols.
(B) Representative images of mitochondrial morphology, showing
the ﬁlamentous (upper panel) or the fragmented (lower panel)
mitochondrial network of ﬁbroblasts grown in DMEM-glucose
or DMEM-galactose. Cells were stained with 100 nM Mito-
tracker-Red CMX-Ros (Invitrogen) for 1/2 hr. The scale bar repre-
sents 10 mm.
(C) Quantiﬁcation of ﬁbroblasts with a normal or fragmented
mitochondrial network in controls (Ct) and patients (Pt) after
incubation in D-MEM þ5 mM galactose for 48 hr.
(D) MTT cell-viability assay. Control (Ct, blue lines) and patients’
(Pt#1, red lines, and Pt#2, brown lines) ﬁbroblasts were grown in
DMEM þ glucose (solid lines) or DMEM þ galactose (dotted lines)
for the times indicated. Absorbance (Abs) is proportional to the
number of viable cells.
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Figure 5. Staurosporine-Induced Cell Death
(A) Quantiﬁcation of altered nuclei in control ﬁbroblasts (Ct), in
ﬁbroblasts from patient #1, Pt(AIF) and from a patient with
SURF1 mutations, Pt(SURF1) after staurosporine treatment
(1 mM for 2 hr). The three panels on the right show representative
ﬁelds of Hoechst-stained nuclei. White arrows indicate cells with
collapsed nuclei.
(B) Samples were the same as in (A), but the treatment consisted of
zVAD (100 mM for 1/2 hr) þ staurosporine (1 mM for 2 hr). As in
(A), the three panels on the right show representative ﬁelds of
Hoechst-stained nuclei. White arrows indicate cells with collapsed
nuclei.
(C) Electron microscopy (EM) image of staurosporine-treated
ﬁbroblasts. Left panel: a control ﬁbroblast shows apoptotic bodies
in the nucleus, typical of caspase-dependent apoptosis; right panel:
a ﬁbroblast from patient #1 shows chromatin condensation of the
nucleus, typical of parthanatos.selection with the neomycin analog G-418, biochemical
assays were performed in triplicate ﬁve times, two with
the ﬁrst transfection, three with the second one. We
observed a consistent, signiﬁcant (p < 0.05) recovery of
biochemical activities, by approximately 55% for cIII
and 35% for cIV, in comparison to mock-transfected cells
(Table 1), again indicating a direct link between mutant
AIFR201 del and multiple RC defects.
In order to investigate the effects of AIFR201 del on pro-
grammed cell death, we challenged AIFR201 del mutant
and control ﬁbroblasts with staurosporine (1 mM for
2 hr), a protein-kinase C inhibitor that induces cell deathThe Amthrough mitochondrion-mediated pathways. In stauro-
sporine-treated AIFR201 del ﬁbroblast cells we observed
a markedly higher number of morphologically altered
nuclei than in identically treated control ﬁbroblasts
(Figure 5A). In cells pretreated with z-VAD-FMK (100 mM
for 1/2 hr), a general inhibitor of caspases, the staurospor-
ine-induced cell death was nearly absent in control ﬁbro-
blasts, whereas as many as 34% of AIFR201 del mutant cells
still displayed nuclear alterations (Figure 5B). Electron
microscopy (EM) images showed a high degree of chro-
matin condensation, typical of parthanatos, in treated
mutant ﬁbroblasts, but hardly any cell had apoptoticerican Journal of Human Genetics 86, 639–649, April 9, 2010 645
Figure 6. TUNEL, Caspase 3 Immuno-
staining, and EM in Skeletal Muscle
(A, B, and D–F) TUNEL þ DAPI staining of
skeletal muscle nuclei in skeletal muscle
from patient #2 and three disease controls
(DMD: from a patient with Duchenne
muscular dystrophy; mtDNA del: from
a patient with a large heteroplasmic dele-
tion of mtDNA; TK2: from a patient who
is compound heterozygote for two patho-
genic mutations in the TK2 gene). TUNEL-
positive nuclei are in green, whereas
TUNEL-negative nuclei are in blue, corre-
sponding to DAPI staining. Numerous
TUNEL-positive are present in patient #2;
two TUNEL-positive green nuclei are
present in the DMD muscle; no TUNEL-
positive nuclei are detected in mtDNA del
or TK muscle specimens.
(C) Anti-Caspase 3 immunostaining of
muscle from patient #2 revealed by the
diamino-benzidine (DAB) method. No
Cas-3-positive ﬁbers were detected. In the
insets of (B), (D), and (F), we show the
same anti-Cas 3 immunostaining carried
out in the corresponding muscle speci-
mens. Only the DMD muscle shows a few
Cas-3-positive, brown ﬁbers.
(E) EM image of a nucleus with chromatin
condensation in muscle tissue from
patient #2.bodies (Figures 5C and 5D), as are described in caspase-
dependent apoptosis. Likewise, in mutant cells we found
marked membrane disruption (not shown), another
morphological hallmark speciﬁc to parthanatos.21 In order
to establish whether staurosporine-induced parthanatos
was due to the direct effect of mutant AIFR201 del or was
rather a consequence of the RC defects found in mutant
AIFR201 del ﬁbroblasts, we challenged with staurosporine
four ﬁbroblast cell lines, each displaying severe, isolated
defects of RC activities, namely cI (because of a pathogenic
homoplasmic mutation in the mtDNA ND1 gene [MIM
*516000]), cII (because of a pathogenic mutation in
SDHAF1, a cII-speciﬁc assembly factor [MIM *612848]),
cIII (because of pathogenic mutations in BCS1L, a cIII-
speciﬁc assembly factor [MIM *603647]), and cIV (because
of pathogenic mutations in SURF1, a cIV-speciﬁc assembly
factor [MIM *185620]). Interestingly, although cI-, cII-, and
cIII-defective ﬁbroblasts reacted to staurosporine like the
normal control ﬁbroblasts (not shown), the cIV-defective
ﬁbroblasts displayed up to 80% more condensed nuclei
than control ﬁbroblasts. This effect was dramatically
reduced (to approximately 30%), but not completely abol-
ished, by pre-exposure to z-VAD-FMK (Figures 5A and 5B).
Therefore, unlike other severe OXPHOS defects, in both646 The American Journal of Human Genetics 86, 639–649, April 9, 2010AIFR201 del and SURF1 mutant cells,
the higher propensity to staurospor-
ine-induced cell death seems to occur,
at least in part, through a caspase-
independent mechanism, probablymediated by AIF. Further investigation will need to clarify
the functional relationship that our Staurosporine
(5z-VAD-FMK)-based experiments in AIFR201 del and
SURF1 mutant cells suggest exists between AIF and either
SURF1 or cIV, as well as the mechanism behind it.
Taken together, these results indicate that (i) the AIFR201
del ﬁbroblasts are much more sensitive to apoptotic stimuli
than control cells and (ii) cell death occurs predominantly
via caspase-independent, AIF-mediated parthanatos. To
further support this idea, we analyzed the muscle biopsy
of patient #2 by using the TUNEL assay, which visualizes
DNA fragmentation in situ. Numerous nuclei stained
positive to TUNEL in the patient’s specimen (Figure 6A),
whereas hardly any staining was detected in a normal
control muscle (not shown) or in three disease control
muscle biopsies: (i) in amuscle affected by a nonmitochon-
drial muscular dystrophy, that is, Duchenne muscular
dystrophy (DMD, MIM #310200) (Figure 6B); (ii) in a
muscle biopsy from a patient affected by Kearns-Sayre
syndrome (MIM #530000) due to a 12000 bp mtDNA dele-
tion (Figure 6D); (iii) in amuscle from a child withmultiple
RC defects due to severe mtDNA depletion associated with
two heterozygous allelic mutations in the TK2 gene (MIM
*188250), encoding the mitochondrion-speciﬁc
thymidine kinase isoform 2 (MIM #609560) (Figure 6F).
Conversely, staining with an anti-caspase 3 antibody was
virtually negative in all specimens, including the muscle
biopsy of our patient (Figure 6C), again indicating that
execution of programmed cell death by mutant AIFR201 del
proceeds through caspase-independent parthanatos. The
insets of Figures 6B, 6D, and 6F show the results of anti-
Cas 3 immunostaining in the disease control muscle spec-
imens. Only the DMDmuscle showed a few Cas-3-positive
ﬁbers, whereas no anti-Cas 3-positive ﬁbers were detected
in muscle specimens carrying the mtDNA deletion or the
TK2 mutation. These results were further conﬁrmed by
ultrastructural studies (Figure 6E) that showed chromatin
condensation in several nuclei of the muscle biopsy of
patient #2.
Prolonged amelioration of clinical conditions by ribo-
ﬂavin supplementation was reported in patient #1.
Because AIF is a FAD-dependent ﬂavoprotein, this effect
could well be explained by stabilization and partial func-
tional correction of the mutant protein by increased avail-
ability of the FAD precursor vitamin, i.e., riboﬂavin. In
support to this hypothesis, we found marked correction
of the cIII and cIV defects in AIFR201 del immortalized
mutant cells treated with riboﬂavin (2 mg/liter in DMEM
medium) for one week (þ74% and þ21%, respectively,
compared to pretreatment values) (Table 1). In addition,
signiﬁcant recovery of the ﬁlamentous network and
improvement in cell viability was obtained in riboﬂavin-
treated mutant ﬁbroblasts under galactose medium
(Figure S3), whereas hardly any difference was observed
in the percentage of condensed nuclei in riboﬂavin-treated
versus untreated mutant cells, both challenged with Staur-
osporine (not shown). In spite of this latter result, the data
altogether offer rational, evidence-based support for ribo-
ﬂavin treatment in AIF mutant subjects.
Finally, we asked whether inactivation of the AIFR201 del
allele in tissues of the two healthy monozygotic twin
mothers had occurred randomly or under selective pres-
sure due to the deleterious effects caused by the AIFR201 del
in the hemizygous mutant offspring. An X-chromosome-
inactivation test based on DNA methylation (HUMARA-
PCR assay) showed that skewed inactivation22 was present
in blood lymphocytes from both individuals and was
associated with virtually no expression of the AIFR201 del
transcript. However, the X-inactivation pattern was less
skewed or not skewed at all in two other cell types (oral
and urinary mucosal epithelial cells) (Table S2), suggesting
variable sensitivity of different cell types to the deleterious
effects of AIFR201 del expression.
In conclusion, we found and characterized a human AIF
mutation clearly associated with (i) a mitochondrial early-
onset encephalomyopathy, (ii) OXPHOS failure caused by
multiple RC defective activities and tissue-speciﬁc mtDNA
depletion, and (iii) increased susceptibility to parthanatos,
the AIF-mediated programmed cell death. It is difﬁcult for
the moment to establish the quantitative contribution of
these three molecular abnormalities to the clinical pheno-The Amtype, but we favor the hypothesis that instability of
mutant AIFR201 del ultimately causes destabilization of the
innermitochondrial membrane and damage of the respira-
tory chain structures and activities. The latter are possibly
consequent to a combination of a direct effect of AIFR201 del
on the integrity of the inner mitochondrial membrane, as
well as to the reduction of the mtDNA copy number. The
existence of an independent pathogenic mechanism,
based on increased propensity to cell death by mutant
AIFR201 del, is supported by experimental evidence from
our in vitro DNA-binding assays, as well as increased cas-
pase-independent nuclear condensation and DNA frag-
mentation shown in both mutant ﬁbroblasts and muscle
ﬁbers. In addition, in silico structural prediction, in vitro
characterization of the recombinant mutant protein, and
ex vivo correction of RC defects by expression of the
wild-type protein in mutant cell lines all converge to
provide solid evidence that the AIFR201 del mutation is
indeed pathogenic and responsible for the human disease.
This is the ﬁrst example of a human mitochondrial ence-
phalomyopathy directly linked to impaired control of
mitochondrion-driven programmed cell death. The effect
of AIFR201 del on RC activities in humans was similar, but
not identical, to that caused by reduced AIF expression in
the Harlequin (Hq) mouse strain, a spontaneous model
of AIF deﬁciency due to a retroviral insertion into the
AIFM1 gene. The 80% reduction in the normal AIF protein
expression found in the Hq model23 causes progressive
degeneration of cerebellar and retinal neurons, leading
to ataxia and blindness, and is associated with moderate
reduction of complex I activity, restricted to affected
tissues.24 Neither a defect of cI in liver and heart nor
defects of cIII and cIV in brain and retina were reported
in the Hqmodel; the mtDNA copy number was apparently
normal in Hq embryonic stem cells, but no data are avail-
able for mtDNA quantiﬁcation in affected tissues. The
multiple RC defects, predominantly affecting cIII and cIV
activities, and the mtDNA depletion detected in skeletal
muscle of our patients do suggest a more complex mecha-
nism of damage of the RC and mtDNA in the human
syndrome. The differences between the Hq mouse versus
human patients are possibly due, at least in part, to the
different genetic lesions affecting AIF. In contrast to the
Hq mouse mutation, the R201 del mutation does not
reduce expression of AIF but rather determines a qualita-
tively abnormal behavior by affecting both redox and
DNA-binding properties of the protein. Nevertheless, in
both Hq mouse and human patients, the mechanism by
which mutant AIF deleteriously affects the RC activity is
presently unknown. In humans, the RC defects and the
mtDNA reduction vary according to the cell type and
OXPHOS demand, therefore favoring the idea that AIF
can inﬂuence RC and mtDNA integrity by taking part in
a complex, possibly tissue-speciﬁc control network that
might (a) act on the stability of mitochondrial membrane
structures and shape,25 (b) regulate the levels of ROS and
the mitochondrial redox state, or (c) combine botherican Journal of Human Genetics 86, 639–649, April 9, 2010 647
mechanisms. Although the constitutive knockout of AIF is
embryonic lethal in mice, an isolated partial cI defect, or
combined partial cI and cIV defects, have been reported
in muscle and heart, respectively, in a cardiac- and skel-
etal-muscle-speciﬁc conditional AIF knockout mouse
model, again suggesting that the biochemical effects of
defective AIF on RC activities might vary in different
tissues and organisms.26 No mtDNA quantiﬁcation was re-
ported in these conditional models.
Physical interactions betweenAIF and RC complexes and
between AIF and OPA1, a morphogenetic and apoptosis
controller of mitochondria, have been proposed to partici-
pate in the pathogenesis of DOA (dominant optic atrophy,
MIM #165500), a condition associated with OPA1 muta-
tions.27 Although we failed to replicate these data in our
conditions (not shown) and found no obvious abnormali-
ties in the composition of OPA1 isoforms in AIFR201 del
mutant ﬁbroblasts (Figure S4), the possible role of AIF in
morphogenesis ofmitochondria andRCstabilization is sug-
gested by disruption of the mitochondrial network in our
mutant cells grown in galactose and by the partial mtDNA
depletion that suggests instability of the mitochondrial
nucleoid structure. In addition, although the role of AIFsol
in parthanatos is well documented and ﬁrmly established,
the role of AIFmit as a NADH oxidase ﬂavoprotein is
completely unknown, as is the correlation, if any, between
these two functions. There is clearly more work to be done
on the multiple homeostatic and metabolic roles of this
intriguing factor so thatwe can fully understand themolec-
ular and cellular pathogenesis associatedwith its deﬁciency
or defect. The relation between AIF and RC activity, estab-
lished by investigation of both mouse and human AIF-
related disorders, offers to future research an interesting
and further exploitable clue. Finally, we observed in
patients, and showed quantitatively in mutant cell lines,
that riboﬂavin supplementation can partially correct
increased cell deathand severe respiratory-chaindeﬁciency.
This result, which has relevant implication for therapy, is
most likely due to the fact that AIF is a FAD-containing
protein whose redox activity is strictly required for normal
mitochondrial functioning.28 Because the ﬂavin binding is
partially impaired inAIFR201 del, themutant cells and organ-
isms could beneﬁt from higher availability of FAD, which
can be achieved by a simple increase in the supply of its
vitamin precursor.Supplemental Data
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